(Following paragraph added on Sep26, 2014) A lesser risk (because that only happens once in a blue moon in biotech) to the numbers would be in case the company actually decided to return its cash to shareholders and close up shop. Under that scenario, the Series F Convertible Preferred Stock Holders would claim and thereby take off $10M from the cash balance.
Thursday, September 25, 2014
Regado Biosciences Should Trade Up Over 30% within 3-5 Months
(Following paragraph added on Sep26, 2014) A lesser risk (because that only happens once in a blue moon in biotech) to the numbers would be in case the company actually decided to return its cash to shareholders and close up shop. Under that scenario, the Series F Convertible Preferred Stock Holders would claim and thereby take off $10M from the cash balance.
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.
17 comments:
The major risks are year end bonuses to the executives and/or the company starts over its biotech adventure with a new developmental program.
Wall St saw the money before it precipitated the spectacular 90% fall in order to get control of it.
How is it you are happy to call this out with a heavy disclaimer but have made no mention of approx. 50% gains in ALNY over the last three months?
Beware the bust out. Hence the disclaimer I say.
Sure, stocks selling for less than cash are good all things being equal but things aren't equal. People still want positive drug prospects with a biotech, not a bank. It would have been better if you emphasized why you still think the company may have good prospects rather than mainly focusing on cash.
QLTI did something vaguely similar in returning a bunch of money to shareholders. Circumstances were a bit different and it took an activist investor to lead the charge.
'People still want positive drug prospects with a biotech, not a bank.'
That's exactly what I think is happening here with the low stock price. The prospect that management can find a decent biotech story for not much money is not priced in at all. I think that's shortsighted.
Reverse an Aussie bio in to it. They're all broke and as cheap as chips with many at PII, beginning PIII.
Which one would you rate Dirk?
Plastic please reverse a sock into it.
Benitec would be an ideal fit, don't you think?
God knows they need as much help as they can get to fight the patent claims and prosecute Voyager for infringement. ROFLMAO.
Dirk? Any opinion?
I own Benitec. Weren't they legally required to file the annual report to shareholders by end of September?
To the previous poster, can I respectfully ask what planet it is you are actually living on?
Nobody needs to file a thing when they no longer exist...except in name.
The report is due by law by the end of October on all planets. This is the site to come for to get the most Benitec hate.
The tech is beyond solid, they will learn how to become a better clinical company and BLT longs will be happy they held. NSCLC is paid for and TT-034 as well, why the hate?
'The report is due by law by the end of October on all planets.'
End of October is still 4 weeks away.
33.61 mil outstanding shares / cash 40 mil after Preferred 10 mil thats $1.20 per shares
RGDO I went in at 1.03 should have sold at 1.18 the first day, but I did sell for profit and take this VERY shaky money off the table. Good luck on this one, but the upside is NOWHERE near what you think it is DH. Way to crappy a company and management are crooks, still very real possibility it goes to .50 to .70 ahead of all the lawsuits (deserved). BTW DH using RNAi on cholesterol is NEVER going to be the method as it obliterates it all versus a knockdown to beneficial levels. Cholesterol is amazingly beneficial and it looks like ESPR has a blockbuster for dealing with statin intolerance. Good luck RGDO longs, that is one stinkin dog!
.50-.60??..where did you get that number from? I dont think so..going to 1.50 soon
.50-.60 look at other bio stocks..lolcompany has cash to shops..if or when trials restarts rgdo sky rocket..its all about risk/rewards..yes you will be crying sold at $1 ..for me longs and patience..will payoff bigtime..
RGDO is looking like it ain't going anywhere except burning cash...good luck but there are a ton of better places to be than waiting on par value to pay off....glad i did a two day quick hit and got OUT!
Post a Comment